Catherine C Lee

US Patent:

54222613, Jun 6, 1995

Filed:

Apr 16, 1993

Appl. No.:

8/049015

Inventors:

Catherine T. Lee - Laguna Hills CA
Cynthia Hornacek - Trabuco cyn CA
Tan T. Dinh - Garden Grove CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

C12N 950
C12N 948
C12N 500
A61K 3762

US Classification:

435219

Abstract:

Proteolytic enzyme compositions and processes for digesting connective tissue are disclosed. The enzyme compositions include collagenase, which is essentially free of toxins and non-collagen specific components, and chymopapain, which is essentially free of toxins. The enzyme compositions are used for dissociating microvessel cells from connective tissue. Recovered microvessel cells are incorporated into artificial vessel grafts. The enzyme compositions preferably contain an aqueous mixture of collagenase having an activity of about 43 nkat/ml to about 51 nkat/ml, and chymopapain having an activity of about 0. 22 nkat/ml to about 0. 44 nkat/ml.

US Patent:

53325036, Jul 26, 1994

Filed:

Apr 16, 1993

Appl. No.:

8/073272

Inventors:

Catherine Lee - Laguna Hills CA
Cynthia Hornacek - Trabuco Cyn. CA
Tan T. Dinh - Garden Grove CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

B01D 1508

US Classification:

210635

Abstract:

A process for purifying crude collagenase is disclosed. The collagenase purification process includes providing a stabilized crude collagenase solution containing collagenase, pigment, toxins, bacterial materials, and proteolytic enzyme impurities including clostripain, trypsin, and caseinase. The stabilized collagenase solution is applied to hydroxylapatite packing. pigment and caseinase are eluted with a first solution comprising about 0. 05 M to about 0. 3 M phosphate buffer, and then collagenase, trypsin, and clostripain are eluted with a second solution comprising about 0. 35 M to about 0. 5 M phosphate buffer to provide a first collected solution. The first collected solution is then applied to gel filtration packing and collagenase and clostripain are eluted with a neutral pH buffer solution, to provide a second collected solution. The second collected solution is then applied to Reactive Red 120-Agarose packing and collagenase is eluted with a neutral pH buffer solution to provide purified collagenase. The process provides extremely pure collagenase in high yield with reduced consumption of eluting solutions and avoids unpredictable gradient eluting techniques.

US Patent:

54242088, Jun 13, 1995

Filed:

Sep 23, 1994

Appl. No.:

8/311383

Inventors:

Catherine T. Lee - Laguna Hills CA
Cynthia Hornacek - Trabuco Cyn CA
Tan T. Dinh - Garden Grove CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

C07G 1500
C12N 500
C12N 100
C12N 950

US Classification:

435268

Abstract:

Proteolytic enzyme compositions and processes for digesting connective tissue are provided. The enzyme compositions include collagenase, which is essentially free of toxins and non-collagen specific components, and chymopapain, which is essentially free of toxins. The enzyme compositions are used for dissociating microvessel cells from connective tissue. Recovered microvessel cells are incorporated into artificial vessel grafts. The composition preferrably contains collagenase having an activity of about 43 nkat/ml to about 51 nkat/ml and chymopapin having an activity of about 0. 22 nkat/ml to about 0. 44 nkat/ml.

US Patent:

56703589, Sep 23, 1997

Filed:

Oct 19, 1995

Appl. No.:

8/545439

Inventors:

Catherine T. Lee - Laguna Hills CA
Cynthia Zerfass - Trabuco Canyon CA
Tan Thanh Dinh - Garden Grove CA
Minh T. Ma - Santa Ana CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

C12N 948
C07G 1700
C07G 1500

US Classification:

435212

Abstract:

The activities of chymopapain or papain in enzyme mixtures are inhibited by the addition of glycogen, hyaluronic acid, or desulfated heparin. The process for isolating viable hepatocytes or pancreatic cells by treatment with papain or chymopapain is improved by terminating the treatment by inhibiting the reaction with these polysaccharides. Similarly, the process for removing undesired tissue by treatment with papain or chymopapain is improved by terminating the treatment by inhibiting the reaction with these polysaccharides.

US Patent:

60082925, Dec 28, 1999

Filed:

Dec 2, 1997

Appl. No.:

8/982846

Inventors:

Catherine Ting Lee - Laguna Hills CA
Jun Yang - Dove Canyon CA
Tan Thanh Dinh - Fountain Valley CA
Ernest H. Pfadenhauer - Costa Mesa CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

A61L 2700

US Classification:

525 541

Abstract:

A method for preparing collagenous biological tissues for use as implantable bioprosthetic material, and articles prepared thereby. The method generally comprises the steps of a) contacting the tissue with an aldehyde fixative to effect cross-linking of the connective tissue protein(s) and subsequently b) contacting the tissue with a polyglycidyl ether. The treatment of the crosslinked tissue with the polyglycidyl ether serves to mitigate the tissue's propensity to undergo calcification following implantation in the body.

US Patent:

58911960, Apr 6, 1999

Filed:

Apr 16, 1997

Appl. No.:

8/843504

Inventors:

Catherine Ting Lee - Laguna Hills CA
Jun Yang - Dove Canyon CA

Assignee:

Baxter International Inc. - Deerfield IL

International Classification:

A61L 1700

US Classification:

8 9411

Abstract:

Methods for binding heparin to biological or synthetic materials which are to be implanted within a mammalian body. In instances where connective tissue proteins or other components of the material having adequate carboxyl groups present thereon, the method comprises a) contacting the material with a carboxyl-activating agent, b) contacting the material with a polyamine compound to form amide-bound polyarnine side chains at the sites of the previously activated carboxyl groups, and c) contacting the material with heparin such that heparin will become bound to the amino groups on the polyamine side chains. In other applications wherein the connective tissue proteins or other molecular entities of the material are devoid of or deficient in carboxyl groups, the method will comprise a) contacting the material with a carboxyl-activating agent in combination with a polyamine compound which has functional carboxyl groups thereon such that at least some of the functional carboxyl groups of the polyamine compound will become activated and will react with some of the amino groups on the polyamine compounds to form a polyamine network interlocked within the molecular structure of the material, and b) contacting the material with heparin such that heparin will become bound to amino groups on the polyamine network.

US Patent:

20190194140, Jun 27, 2019

Filed:

Mar 4, 2019

Appl. No.:

16/292050

Inventors:

- San Diego CA, US
Catherine Yuling Lee - San Diego CA, US
Yiwei Li - Potomac MD, US

International Classification:

C07D 223/20
A61K 47/34
A61K 9/00
A61K 47/02
A61K 47/10
C07D 223/18
A61K 47/36
A61K 47/38
A61K 47/32
A61P 27/16

Abstract:

The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.

US Patent:

20180273483, Sep 27, 2018

Filed:

Apr 10, 2018

Appl. No.:

15/950065

Inventors:

- San Diego CA, US
Catherine Yuling Lee - San Diego CA, US
Yiwei Li - Potomac MD, US

International Classification:

C07D 223/20
A61K 9/00
A61K 47/34
A61K 47/38
A61K 47/36
A61K 47/10
A61K 47/32
A61K 47/02
A61P 27/16

Abstract:

The present disclosure provides crystalline Compound I and crystalline Compound II, pharmaceutical compositions comprising one of said crystalline compounds suitable for intratympanic administration, and methods for treating otic disorders using the crystalline compounds and the pharmaceutical compositions.